Cited by 2,340Hemoglobinopathies and Related DisordersBlood groups and transfusionHemophilia Treatment and Research

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia

Open access

Charache, Samuel, Terrin, Michael L., Moore, Richard D., Dover, George J., Barton, Franca B., Eckert, Susan V., McMahon, Robert P., Bonds, Duane R.·1995·New England Journal of Medicine

DOI 10.1056/nejm199505183322001

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: In a previous open-label study of hydroxyurea therapy, the synthesis of fetal hemoglobin increased in most patients with sickle cell anemia, with only mild myelotoxicity. By inhibiting sickling, increased levels of fetal hemoglobin might decrease the frequency of painful crises. METHODS: In a double-blind, randomized clinical trial, we tested the efficacy of hydroxyurea in reducing the frequency of painful crises in adults with a history of three or more such crises per year. The trial was stopped after a mean follow-up of 21 months. RESULTS: Among 148 men and 151 women studied at 21 clinics, the 152 patients assigned to hydroxyurea treatment had lower annual rates of crises than the 147 patients given placebo (median, 2.5 vs. 4.5 crises per year, P < 0.001). The median times to the first crisis (3.0 vs. 1.5 months, P = 0.01) and the second crisis (8.8 vs. 4.6 months, P < 0.001) were longer with hydroxyurea treatment. Fewer patients assigned to hydroxyurea had chest syndrome (25 vs. 51, P < 0.001), and fewer underwent transfusions (48 vs. 73, P = 0.001). At the end of the study, the doses of hydroxyurea ranged from 0 to 35 mg per kilogram of body weight per day. Treatment with hydroxyurea did not cause any important adverse effects. CONCLUSIONS: Hydroxyurea therapy can ameliorate the clinical course of sickle cell anemia in some adults with three or more painful crises per year. Maximal tolerated doses of hydroxyurea may not be necessary to achieve a therapeutic effect. The beneficial effects of hydroxyurea do not become manifest for several months, and its use must be carefully monitored. The long-term safety of hydroxyurea in patients with sickle cell anemia is uncertain.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199505183322001

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

An introduction to probability theory and its applications
(1958) · Journal of the Franklin Institute · doi:10.1016/0016-0032(58)90688-4 · Cited by 29,621
Applied Regression Analysis
Draper, N. R., & Smith, H. (2005) · Technometrics · doi:10.1198/tech.2005.s303 · Cited by 17,993
Practical Nonparametric Statistics (2nd ed).
Groeneveld, R. A., & Conover, W. J. (1981) · Journal of the American Statistical Association · doi:10.2307/2287607 · Cited by 1,869
Pain in Sickle Cell Disease: Rates and Risk Factors
Platt, O. S., Thorington, B. D., Brambilla, D. J., Milner, P. F., Rosse, W. F., Vichinsky, E., & Kinney, T. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107043250103 · Cited by 1,546
Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.
Platt, O., Orkin, S. H., Dover, G., Beardsley, G. P., Miller, B. A., & Nathan, D. G. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111464 · Cited by 532
Self-citation
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia [see comments]
Charache, S., Dover, G. J., Moore, R. D., Eckert, S. V., Ballas, S., Koshy, M., Milner, P., Orringer, E., Phillips, G., & Platt, O. (1992) · Blood · doi:10.1182/blood.v79.10.2555.2555 · Cited by 438
Self-citation
5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons.
DeSimone, J., Heller, P., Hall, L., & Zwiers, D. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.14.4428 · Cited by 384
Hydroxyurea as an Inhibitor of Human Immunodeficiency Virus-Type 1 Replication
Lori, F., Malykh, A., Cara, A., Sun, D. K., Weinstein, J. N., Lisziewicz, J., & Gallo, R. C. (1994) · Science · doi:10.1126/science.7973634 · Cited by 317
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia [see comments]
Charache, S., Dover, G. J., Moore, R. D., et al. (1992) · Blood · doi:10.1182/blood.v79.10.2555.bloodjournal79102555 · Cited by 301
Self-citation
Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate
Dover, G. J., Brusilow, S. W., & Charache, S. (1994) · Blood · doi:10.1182/blood.v84.1.339.bloodjournal841339 · Cited by 229
Self-citation

Show all 26 references

Research works printed but not linked: 10

Dover GJ, 1994, Blood, 84, 339, 10.1182/blood.V84.1.339.339 · DOI
1994, Blood, 84, 404a
Kalbfleisch JD, Prentice RL. The stastistical analysis of failure time data. New York: John Wiley, 1980:1-20, 70-142.
Ferm VH, 1966, Arch Pathol, 81, 174
Weichselbaum RR, Hallahan DE, Chen GTY. Biological and physical basis to radiation oncology. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR, eds. Cancer medicine. 3rd ed. Vol. 1. Philadelphia: Lea & Febiger, 1993:539-66.
Chemotherapeutic agents. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR, eds. Cancer medicine. 3rd ed. Vol. 1. Philadelphia: Lea & Febiger, 1993:698-814.
Berk PD, Wasserman LR, Fruchtman SM, Goldberg JD. Treatment of polycythemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group. In: Wasserman LR, Berk PD, berlin NI, eds. Polycythemia vera and the myeloproliferative disorders. Philadelphia: W.B. Saunders, 1995:166-94.
Fruchtman SM, 1994, Blood, 84, 518a
Boivin P, 1993, Nouv Rev Fr Hematol, 35, 491
Triadou P, 1994, Nouv Rev Fr Hematol, 36, 367

Sorted by citations

Items 201–300 of 1,004

Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea
Ma, Q., Wyszynski, D. F., Farrell, J. J., Kutlar, A., Farrer, L. A., Baldwin, C. T., & Steinberg, M. H. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500433 · Cited by 125
Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia
Jayabose, S., Tugal, O., Sandoval, C., Patel, P., Puder, D., Lin, T., & Visintainer, P. (1996) · The Journal of Pediatrics · doi:10.1016/s0022-3476(96)70121-x · Cited by 125
Replication stress and mechanisms of CNV formation
Arlt, M. F., Wilson, T. E., & Glover, T. W. (2012) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.01.009 · Cited by 133
Guidelines on red cell transfusion in sickle cell disease Part II : indications for transfusion
Davis, B. A., Allard, S., Qureshi, A., Porter, J. B., Pancham, S., Win, N., Cho, G., Ryan, K. E., & the British Society for Haematology (2016) · British Journal of Haematology · doi:10.1111/bjh.14383 · Cited by 124
“However, given that there is a clear benefit of hydroxycarbamide for ACS prevention (Charache et al, 1995; Thornburg et al, 2012), transfusion should be considered only if hydroxycarbamide is ineffective or contraindicated.”
Horseradish Peroxidase Catalyzed Nitric Oxide Formation from Hydroxyurea
Huang, J., Sommers, E. M., Kim‐Shapiro, D. B., & King, S. B. (2002) · Journal of the American Chemical Society · doi:10.1021/ja012271v · Cited by 126
SYSTEMIC FAT EMBOLISM AND PULMONARY HYPERTENSION IN SICKLE CELL DISEASE
Castro, O. (1996) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70401-9 · Cited by 122
Sickle Red Cell Microrheology and Sickle Blood Rheology
Ballas, S. K., & Mohandas, N. (2004) · Microcirculation · doi:10.1080/10739680490279410 · Cited by 123
Hospitalization rates and costs of care of patients with sickle‐cell anemia in the state of Maryland in the era of hydroxyurea
Lanzkron, S., Haywood, C., Segal, J. B., & Dover, G. J. (2006) · American Journal of Hematology · doi:10.1002/ajh.20703 · Cited by 122
Self-citation
A cell stress signaling model of fetal hemoglobin induction: what doesn't kill red blood cells may make them stronger
Mabaera, R., West, R. J., Conine, S. J., Macari, E. R., Boyd, C. D., Engman, C. A., & Lowrey, C. H. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.06.014 · Cited by 123
Kinetics of sickle cell biorheology and implications for painful vasoocclusive crisis
Du, E., Diez-Silva, M., Kato, G. J., Dao, M., & Suresh, S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424111112 · Cited by 120
Emerging genetic therapy for sickle cell disease
Orkin, S. H., & Bauer, D. E. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-041817-125507 · Cited by 119
Technology Access and Smartphone App Preferences for Medication Adherence in Adolescents and Young Adults With Sickle Cell Disease
Badawy, S. M., Thompson, A. A., & Liem, R. I. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.25905 · Cited by 119
The effect of fetal hemoglobin on the survival characteristics of sickle cells
Franco, R. S., Yasin, Z., Palascak, M. B., Ciraolo, P., Joiner, C. H., & Rucknagel, D. L. (2006) · Blood · doi:10.1182/blood-2005-09-008318 · Cited by 119
Sickle Cell Disease in Sub-Saharan Africa
Williams, T. N. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.11.005 · Cited by 121
Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion
Lagresle‐Peyrou, C., Lefrère, F., Magrin, E., Ribeil, J., Romano, O., Weber, L., Magnani, A., Sadek, H., Plantier, C., Gabrion, A., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.184788 · Cited by 124
Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies
Vinjamur, D. S., Bauer, D. E., & Orkin, S. H. (2018) · British Journal of Haematology · doi:10.1111/bjh.15038 · Cited by 114
“Use of hydroxycarbamide, an S-phase cell cycle inhibitor, results in elevated HbF levels in many patients and decreases the fre- quency and severity of vaso-occlusive episodes (Platt et al, 1984; Charache et al, 1995).”
Background
Update on the use of hydroxyurea therapy in sickle cell disease
Wong, T. E., Brandow, A. M., Lim, W., & Lottenberg, R. (2014) · Blood · doi:10.1182/blood-2014-08-435768 · Cited by 119
RheothRx (Poloxamer 188) Injection for the Acute Painful Episode of Sickle Cell Disease: A Pilot Study
Adams-Graves, P. E., Kedar, A., Koshy, M., Steinberg, M. H., Veith, R. W., Ward, D., Crawford, R., Edwards, S., Bustrack, J. A., & Emanuele, M. (1997) · Blood · doi:10.1182/blood.v90.5.2041 · Cited by 117
Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation
Setty, Y. B. N., Kulkarni, S., Rao, A. K., & Stuart, M. J. (2000) · Blood · doi:10.1182/blood.v96.3.1119.015k53_1119_1124 · Cited by 117
Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice
Almeida, C. B., Scheiermann, C., Jang, J.-E., Prophete, C., Costa, F. F., Conran, N., & Frenette, P. S. (2012) · Blood · doi:10.1182/blood-2012-02-409524 · Cited by 120
Hydroxyurea can eliminate transfusion requirements in children with severe β-thalassemia
Bradai, M., Abad, M. T., Pissard, S., Lamraoui, F., Skopinski, L., & de Montalembert, M. (2003) · Blood · doi:10.1182/blood-2003-01-0117 · Cited by 116
Increased levels of the inflammatory biomarker C‐reactive protein at baseline are associated with childhood sickle cell vasocclusive crises
Krishnan, S., Setty, Y. B. N., Betal, S. G., Vaidyula, V. R., Rao, K., Dampier, C., & Stuart, M. J. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.08013.x · Cited by 118
Lessons From the Stroke Prevention Trial in Sickle Cell Anemia (STOP) Study
Adams, R. J. (2000) · Journal of Child Neurology · doi:10.1177/088307380001500511 · Cited by 115
Guidelines on red cell transfusion in sickle cell disease. Part I: principles and laboratory aspects
Davis, B. A., Allard, S., Qureshi, A., Porter, J. B., Pancham, S., Win, N., Cho, G., & Ryan, K. E. (2016) · British Journal of Haematology · doi:10.1111/bjh.14346 · Cited by 114
“For long-term management, hydroxycarbamide can reduce the need for transfusions and should be considered (Charache et al, 1995).”
Background
Effect of hydroxyurea on growth in children with sickle cell anemia: Results of the HUG-KIDS study
Wang, W. C., Helms, R. W., Lynn, H., Redding‐Lallinger, R., Gee, B. E., Ohene‐Frempong, K., Smith‐Whitley, K., Waclawiw, M. A., Vichinsky, E. P., Styles, L. A., et al. (2002) · The Journal of Pediatrics · doi:10.1067/mpd.2002.121383 · Cited by 114
Peripheral blood neutrophil count and candidacidal activity correlate with the clinical severity of sickle cell anaemia (SCA)
Anyaegbu, C. C., Okpala, I. E., Aken'Ova, Y. A., & Salimonu, L. S. (1998) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1998.tb01036.x · Cited by 114
Oxidative stress in sickle cell disease: An overview of erythrocyte redox metabolism and current antioxidant therapeutic strategies
da Silva, D. G. H., Belini-Junior, E., de Almeida, E. A., & Bonini-Domingos, C. R. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.08.181 · Cited by 118
Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia
Aygün, B., Mortier, N. A., Smeltzer, M. P., Shulkin, B. L., Hankins, J. S., & Ware, R. E. (2012) · American Journal of Hematology · doi:10.1002/ajh.23365 · Cited by 113
Sickle Cell Disease, Vasculopathy, and Therapeutics
Kassim, A. A., & DeBaun, M. R. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-120611-143127 · Cited by 113
Association of Coagulation Activation with Clinical Complications in Sickle Cell Disease
Ataga, K. I., Brittain, J. E., Desai, P. C., May, R., Jones, S., Delaney, J., Strayhorn, D., Hinderliter, A. L., & Key, N. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029786 · Cited by 112
SICKLE CELL DISEASE
Lane, P. A. (1996) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(05)70426-0 · Cited by 112
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
Nand, S., Stock, W., Godwin, J. E., & Fisher, S. G. (1996) · American Journal of Hematology · doi:10.1002/(sici)1096-8652(199605)52:1 · Cited by 112
Hydroxyurea corrects the dysregulated L-selectin expression and increased H2O2 production of polymorphonuclear neutrophils from patients with sickle cell anemia
Benkerrou, M., Delarche, C., Brahimi, L., Fay, M., Vilmer, E., Elion, J., Gougerot-Pocidalo, M.-A., & Elbim, C. (2002) · Blood · doi:10.1182/blood.v99.7.2297 · Cited by 110
Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research
McGann, P. T., Hernandez, A. G., & Ware, R. E. (2016) · Blood · doi:10.1182/blood-2016-09-702324 · Cited by 111
Exposure to Hydroxyurea and Pregnancy Outcomes in Patients With Sickle Cell Anemia
Ballas, S. K., McCarthy, W. F., Guo, N., DeCastro, L. M., Bellevue, R., BARTON, B. A., & Waclawiw, M. A. (2009) · Journal of the National Medical Association · doi:10.1016/s0027-9684(15)31072-5 · Cited by 111
The Acute Chest Syndrome of Sickle Cell Disease
Platt, O. S. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422510 · Cited by 112
Mapping the prevalence of sickle cell and beta thalassaemia in England: estimating and validating ethnic‐specific rates
Hickman, M., Modell, B., Greengross, P., Chapman, C., Layton, M., Falconer, S., & Davies, S. C. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01275.x · Cited by 110
Management of Patients with Sickle Cell Disease Using Transfusion Therapy
Chou, S. T., & Fasano, R. M. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.01.011 · Cited by 112
Fetal haemoglobin in sickle-cell disease: from genetic epidemiology to new therapeutic strategies
Lettre, G., & Bauer, D. E. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01341-0 · Cited by 104
Update on fetal hemoglobin gene regulation in hemoglobinopathies
Bauer, D. E., & Orkin, S. H. (2010) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e3283420fd0 · Cited by 111
PedsQL™ Multidimensional Fatigue Scale in Sickle Cell Disease: Feasibility, Reliability and Validity
Panepinto, J. A., Torres, S., Bendo, C. B., Mccavit, T., Dinu, B., Sherman‐Bien, S., Bemrich-Stolz, C. J., & Varni, J. W. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24776 · Cited by 109
Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia
Auerbach, M., Pappadakis, J. A., Bahrain, H., Auerbach, S. A., Ballard, H. S., & Dahl, N. V. (2011) · American Journal of Hematology · doi:10.1002/ajh.22153 · Cited by 108
Drug discovery and development for rare genetic disorders
Sun, W., Zheng, W., & Simeonov, A. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38326 · Cited by 107
Hydroxyurea in thalassemia intermedia—a promising therapy
Dixit, A., Chatterjee, T., Mishra, P. P., Choudhry, D. R., Mahapatra, M., Tyagi, S., Kabra, M., Saxena, R., & Choudhry, V. P. (2005) · Annals of Hematology · doi:10.1007/s00277-005-1026-4 · Cited by 107
of Neurology affirms the value of this guideline. Outcomes Research Interdisciplinary Working Group: The American Academy Physical Activity, and Metabolism Council; and the Quality of Care and Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Association/American Stroke Association Stroke Council: Cosponsored by the Primary Prevention of Ischemic Stroke: A Guideline From the American Heart
Bushnell, C., Culebras, A., DeGraba, T. J., Goldstein, B. A., Adams, R. J., Alberts, M. J., & Appel, L. J. (2006) · Cited by 108
Fortnightly review: Management of patients with sickle cell disease
Davies, S. C., & Oni, L. (1997) · BMJ · doi:10.1136/bmj.315.7109.656 · Cited by 107
Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities
Brandow, A. M., & Panepinto, J. A. (2010) · Expert Review of Hematology · doi:10.1586/ehm.10.22 · Cited by 106
Pulmonary manifestations of sickle cell disease
Siddiqui, A. K., & Ahmed, S. (2003) · Postgraduate Medical Journal · doi:10.1136/pmj.79.933.384 · Cited by 105
Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.
Yavarian, M., Karimi, M., Bakker, E., Harteveld, C. L., & Giordano, P. C. (2004) · PubMed · Cited by 106
Pathophysiology and therapy for haemoglobinopathies; Part I: sickle cell disease
Madigan, C., & Malik, P. (2006) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399406010659 · Cited by 111
Sickle Cell Disease in the Post Genomic Era: A Monogenic Disease with a Polygenic Phenotype
Driss, A., Asare, K., Hibbert, J. M., Gee, B. E., Adamkiewicz, T. V., & Stiles, J. K. (2009) · Genomics Insights · doi:10.4137/gei.s2626 · Cited by 105
Markers of Severe Vaso-Occlusive Painful Episode Frequency in Children and Adolescents with Sickle Cell Anemia
Darbari, D. S., Onyekwere, O. C., Nouraie, M. S., Minniti, C. P., Luchtman‐Jones, L., RANA, S. R., Sable, C., Ensing, G. J., Dham, N., Campbell, A., et al. (2011) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2011.07.018 · Cited by 105
Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells
Čokić, V. P., Andrić, S. A., Stojilković, S. S., Noguchi, C. T., & Schechter, A. N. (2007) · Blood · doi:10.1182/blood-2007-05-088732 · Cited by 104
Haematological values in homozygous sickle cell disease in steady state and haemoglobin phenotypes AA controls in Lagos, Nigeria
Akinbami, A., Dosunmu, A. O., Adediran, A., Oshinaike, O. O., Adebola, P., & Arogundade, O. (2012) · BMC Research Notes · doi:10.1186/1756-0500-5-396 · Cited by 104
Aqp1 expression in erythroleukemia cells: genetic regulation of glucocorticoid and chemical induction
Moon, C., King, L. S., & Agre, P. C. (1997) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1997.273.5.c1562 · Cited by 104
Physiological reactions of nitric oxide and hemoglobin: A radical rethink
Gross, S. S., & Lane, P. B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.9967 · Cited by 103
Peptide nucleic acid (PNA) binding-mediated induction of human -globin gene expression
Wang, G., Xu, X., Pace, B. S., Dean, D. A., Glazer, P. M., Chan, P., Goodman, S. R., & Shokolenko, I. N. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.13.2806 · Cited by 105
Osteonecrosis of the femoral head in sickle cell disease: prevalence, comorbidities, and surgical outcomes in California
Adesina, O., Brunson, A. M., Keegan, T. H. M., & Wun, T. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017005256 · Cited by 103
Effects of N ‐acetylcysteine on dense cell formation in sickle cell disease
Pace, B. S., Shartava, A., Pack-Mabien, A. V., Mulekar, M., Ardia, A., & Goodman, S. R. (2003) · American Journal of Hematology · doi:10.1002/ajh.10321 · Cited by 103
Correction of Murine Sickle Cell Disease Using γ-Globin Lentiviral Vectors to Mediate High-level Expression of Fetal Hemoglobin
Pestina, T. I., Hargrove, P. W., Jay, D. W., Gray, J. T., Boyd, K. L., & Persons, D. A. (2008) · Molecular Therapy · doi:10.1038/mt.2008.259 · Cited by 103
One hundred years of sickle cell disease
Serjeant, G. R. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08419.x · Cited by 102
The obstetric management of sickle cell disease
Howard, J., & Oteng‐Ntim, E. (2011) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2011.10.001 · Cited by 102
Advances in the Treatment of Sickle Cell Disease
Kapoor, S., Little, J. A., & Pecker, L. H. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.08.001 · Cited by 110
Hydroxyurea and Arginine Therapy: Impact on Nitric Oxide Production in Sickle Cell Disease
Morris, C. R., Vichinsky, E. P., van Warmerdam, J., Machado, L., Kepka‐Lenhart, D., Morris, S. M., & Kuypers, F. A. (2003) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200308000-00008 · Cited by 102
Pulmonary Complications of Sickle Cell Anemia
Minter, K. R., & Gladwin, M. T. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.11.2104101 · Cited by 102
Impact of family income and sickle cell disease on the health-related quality of life of children
Panepinto, J. A., Pajewski, N. M., Foerster, L. M., Sabnis, S. S., & Hoffmann, R. G. (2008) · Quality of Life Research · doi:10.1007/s11136-008-9412-8 · Cited by 101
Pathophysiologically based drug treatment of sickle cell disease
Steinberg, M. H. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.02.007 · Cited by 101
Six Months of Hydroxyurea Reduces Albuminuria in Patients with Sickle Cell Disease
Bartolucci, P., Habibi, A., Stehlé, T., Liberto, G. D., Rakotoson, M. G., Gellen‐Dautremer, J., Loric, S., Moutereau, S., Sahali, D., Wagner‐Ballon, O., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014111126 · Cited by 100
Hydroxyurea in children with sickle cell disease: Practice patterns and barriers to utilization
Brandow, A. M., Jirovec, D. L., & Panepinto, J. A. (2010) · American Journal of Hematology · doi:10.1002/ajh.21749 · Cited by 100
Mortality in sickle cell patients on hydroxyurea therapy
Bakanay, Ş. M., Dainer, E., Clair, B., Adekile, A. D., Daitch, L., Wells, L., Holley, L., Smith, D. A., & Kutlar, A. (2004) · Blood · doi:10.1182/blood-2004-01-0322 · Cited by 100
Enalapril and hydroxyurea therapy for children with sickle nephropathy
Fitzhugh, C. D., Wigfall, D. R., & Ware, R. E. (2005) · Pediatric Blood & Cancer · doi:10.1002/pbc.20296 · Cited by 99
Redox-dependent impairment of vascular function in sickle cell disease
Aslan, M., & Freeman, B. Α. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.08.014 · Cited by 97
Involvement of p38 kinase in hydroxyurea-induced differentiation of K562 cells.
Park, J. I., Choi, H.-K., Jeong, J., Han, J. Y., & Kim, I. H. (2001) · PubMed · Cited by 99
Three-Year Follow-Up of Hydroxyurea Treatment in Severely Ill Children with Sickle Cell Disease
de Montalembert, M., Belloy, M., Bernaudin, F., Gouraud, F., Capdeville, R., Mardini, R., Philippe, N., Jaïs, J., Bardakdjian‐Michau, J., Ducrocq, R., et al. (1997) · The American journal of pediatric hematology/oncology · doi:10.1097/00043426-199707000-00009 · Cited by 99
Hydroxyurea induces de novo copy number variants in human cells
Arlt, M. F., Ozdemir, A. C., Birkeland, S. R., Wilson, T. E., & Glover, T. W. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109272108 · Cited by 99
Targeted Therapeutic Strategies for Fetal Hemoglobin Induction
Sankaran, V. G. (2011) · Hematology · doi:10.1182/asheducation-2011.1.459 · Cited by 102
Reproductive issues in sickle cell disease
Smith‐Whitley, K. (2014) · Hematology · doi:10.1182/asheducation-2014.1.418 · Cited by 98
Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea
Hankins, J. S., Helton, K. J., McCarville, M. B., Li, C., Wang, W. C., & Ware, R. E. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21271 · Cited by 98
NTP‐CERHR Expert Panel Report on the reproductive and developmental toxicity of hydroxyurea
Liebelt, E. L., Balk, S. J., Faber, W. D., Fisher, J. W., Hughes, C. L., Lanzkron, S., LEWIS, K. M., Marchetti, F., Mehendale, H. M., Rogers, J. M., et al. (2007) · Birth Defects Research Part B Developmental and Reproductive Toxicology · doi:10.1002/bdrb.20123 · Cited by 98
A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease
Pule, G. D., Mowla, S., Novitzky, N., Wiysonge, C. S., & Wonkam, A. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1078235 · Cited by 103
“Initial trial showed that HU was associated with decreases in the frequencies of painful episodes, acute chest syndrome, hospitalization and transfusions [28].”
Background
Asthma and acute chest in sickle‐cell disease
Boyd, J. H., Moinuddin, A., Strunk, R. C., & DeBaun, M. R. (2004) · Pediatric Pulmonology · doi:10.1002/ppul.20066 · Cited by 97
Levels of Endothelial, Neutrophil and Platelet-Specific Factors in Sickle Cell Anemia Patients during Hydroxyurea Therapy
Saleh, A. W., Hillen, H. F. P., & Duits, A. J. (1999) · Acta Haematologica · doi:10.1159/000040964 · Cited by 97
Management of sickle cell disease in pregnancy. A British Society for Haematology Guideline
Oteng‐Ntim, E., Pavord, S. R., Howard, R., Robinson, S. E., Oakley, L., Mackillop, L. H., Pancham, S., & Howard, J. (2021) · British Journal of Haematology · doi:10.1111/bjh.17671 · Cited by 96
“SCD comprises a group of conditions Correspondence: Jo Howard, BSH Guidelines Administrator, British Society for Haematology, 100 White Lion Street, London N1 9PF, UK.”
BackgroundInfluential
A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia
Thornburg, C. D., Dixon, N., Burgett, S. E., Mortier, N. A., Schultz, W. H., Zimmerman, S. A., Bonner, M. J., Hardy, K. K., Calatroni, A., & Ware, R. E. (2008) · Pediatric Blood & Cancer · doi:10.1002/pbc.21738 · Cited by 96
Stroke Prevention and Treatment in Sickle Cell Disease
Adams, R. (2001) · Archives of Neurology · doi:10.1001/archneur.58.4.565 · Cited by 96
Induction of Fetal Hemoglobin in the Treatment of Sickle Cell Disease
Fathallah, H., & Atweh, G. F. (2006) · Hematology · doi:10.1182/asheducation-2006.1.58 · Cited by 95
The Biophysics of Sickle Cell Hydroxyurea Therapy
Eaton, W. A., & Hofrichter, J. (1995) · Science · doi:10.1126/science.7539154 · Cited by 96
Provider Barriers to Hydroxyurea Use in Adults with Sickle Cell Disease: A Survey of the Sickle Cell Disease Adult Provider Network
Lanzkron, S., Rand, C. S., Haywood, C., & Hassell, K. L. (2008) · Journal of the National Medical Association · doi:10.1016/s0027-9684(15)31420-6 · Cited by 95
Understanding the Shape of Sickled Red Cells
Christoph, G. W., Hofrichter, J., & Eaton, W. A. (2004) · Biophysical Journal · doi:10.1529/biophysj.104.051250 · Cited by 97
Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells
Čokić, V. P. (2006) · Blood · doi:10.1182/blood-2005-11-4454 · Cited by 94
Sickle Cell Disease in Children
Meier, E. R., & Miller, J. L. (2012) · Drugs · doi:10.2165/11632890-000000000-00000 · Cited by 97
Frequency of Hospitalizations for Pain and Association With Altered Brain Network Connectivity in Sickle Cell Disease
Darbari, D. S., Hampson, J. P., Ichesco, E., Kadom, N., Vézina, G., Evangelou, I. E., Clauw, D. J., Taylor, J. G., & Harris, R. E. (2015) · Journal of Pain · doi:10.1016/j.jpain.2015.07.005 · Cited by 95
Long-term treatment follow-up of children with sickle cell disease monitored with abnormal transcranial Doppler velocities
Bernaudin, F., Verlhac, S., Arnaud, C., Kamdem, A., Hau, I., Leveillé, E., Vasile, M., Kasbi, F., Madhi, F., Fourmaux, C., et al. (2016) · Blood · doi:10.1182/blood-2015-10-675231 · Cited by 92
Molecular basis of erythrocyte adhesion to endothelial cells in diseases
Wautier, J., & Wautier, M. (2013) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-2012-1572 · Cited by 92
Pathological basis of symptoms and crises in sickle cell disorder: implications for counseling and psychotherapy
Ilesanmi, O. O. (2010) · Hematology Reports · doi:10.4081/hr.2010.e2 · Cited by 90
An Evidence-Based Approach to the Treatment of Adults with Sickle Cell Disease
Lottenberg, R., & Hassell, K. L. (2005) · Hematology · doi:10.1182/asheducation-2005.1.58 · Cited by 91
Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease
Odièvre, M., Bony, V., Benkerrou, M., Lapouméroulie, C., Alberti, C., Ducrocq, R., Jacqz-Aigrain, É., Élion, J., & Cartron, J. (2008) · Haematologica · doi:10.3324/haematol.12070 · Cited by 90
Acute chest syndrome: sickle cell disease
Paul, R. N., Castro, O. L., Aggarwal, A., & Oneal, P. A. (2011) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2011.01647.x · Cited by 91
How we treat sickle hepatopathy and liver transplantation in adults
Gardner, K., Suddle, A. R., Kane, P., O’Grady, J., Heaton, N. D., Bomford, A. B., & Thein, S. L. (2014) · Blood · doi:10.1182/blood-2013-12-542076 · Cited by 90
“Hydroxyurea, beneficial in patients with frequent painful crises and acute chest syndrome, has not been shown to reduce the frequency of hepatic sequestration crises.((20)) Further work is needed on exploring the preventative effects of hydroxyurea on organ damage including sickle hepatopathy,”
Background
Sickle Cell Disease, a Review
Tebbi, C. K. (2022) · Hemato · doi:10.3390/hemato3020024 · Cited by 110

Authors: Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R.
Affiliations: Johns Hopkins University (US)
Maryland Medical Research Institute (US)
National Heart, Lung, and Blood Institute (US)
ORCID: Terrin, Michael L.
Moore, Richard D.
Barton, Franca B.
McMahon, Robert P.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1995-05-18
Volume: 332
Issue: 20
Pages: 1317-1322
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199505183322001
OpenAlex: W2313541759
Semantic Scholar: 2c0939e2f6480b519903bb15870e5b894887e70d
Cited by: 2,340
References: 26
Citations by year: 2026: 67 · 2025: 97 · 2024: 77 · 2023: 88 · 2022: 95 · 2021: 92 · 2020: 80 · 2019: 78 · 2018: 85 · 2017: 104 · 2016: 114 · 2015: 101 · 2014: 82 · 2013: 79 · 2012: 73
FWCI: 34.43
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Bristol-Myers Squibb
National Institutes of Health (5u01hl045696-05)
National Heart, Lung, and Blood Institute (UO1-HL 45696, UO1 HL 45692, U01HL045692)
National Center for Research Resources (RR00046, M01RR000046)
Topics: Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
Health Sciences › Medicine › Hematology › Blood groups and transfusion
Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
Keywords: hydroxyurea, sickle cell disease, vaso-occlusive crisis, fetal hemoglobin, blood transfusion, myelosuppression, treatment efficacy, adverse effects
MeSH terms: Adult, Anemia, Sickle Cell, Double-Blind Method, Female, Follow-Up Studies, Humans, Hydroxyurea, Male, Pain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks